- Home
- HPP vs ESPR Comparison
HPP vs ESPR Comparison
Compare HPP & ESPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HPP
- ESPR
- Stock Information
- Founded
- HPP 2009
- ESPR 2008
- Country
- HPP United States
- ESPR United States
- Employees
- HPP N/A
- ESPR N/A
- Industry
- HPP Real Estate
- ESPR Biotechnology: Pharmaceutical Preparations
- Sector
- HPP Finance
- ESPR Health Care
- Exchange
- HPP Nasdaq
- ESPR Nasdaq
- Market Cap
- HPP 481.6M
- ESPR 399.0M
- IPO Year
- HPP 2010
- ESPR 2013
- Fundamental
- Price
- HPP $2.94
- ESPR $2.19
- Analyst Decision
- HPP Hold
- ESPR Buy
- Analyst Count
- HPP 11
- ESPR 5
- Target Price
- HPP $5.95
- ESPR $7.30
- AVG Volume (30 Days)
- HPP 6.6M
- ESPR 8.9M
- Earning Date
- HPP 02-10-2025
- ESPR 11-07-2024
- Dividend Yield
- HPP 3.41%
- ESPR N/A
- EPS Growth
- HPP N/A
- ESPR N/A
- EPS
- HPP N/A
- ESPR N/A
- Revenue
- HPP $847,713,000.00
- ESPR $295,451,000.00
- Revenue This Year
- HPP N/A
- ESPR $186.90
- Revenue Next Year
- HPP N/A
- ESPR $31.10
- P/E Ratio
- HPP N/A
- ESPR N/A
- Revenue Growth
- HPP N/A
- ESPR 187.12
- 52 Week Low
- HPP $2.39
- ESPR $1.58
- 52 Week High
- HPP $9.86
- ESPR $3.94
- Technical
- Relative Strength Index (RSI)
- HPP 37.31
- ESPR 42.08
- Support Level
- HPP $2.39
- ESPR $2.12
- Resistance Level
- HPP $3.33
- ESPR $2.54
- Average True Range (ATR)
- HPP 0.30
- ESPR 0.39
- MACD
- HPP -0.05
- ESPR -0.13
- Stochastic Oscillator
- HPP 36.82
- ESPR 16.67
About HPP Hudson Pacific Properties Inc.
Hudson Pacific Properties Inc is a real estate investment trust that acquires, operates, and owns office buildings and media and entertainment properties, such as sound stages, on America's West Coast. The company focuses on developed, urban markets in Northern California, Southern California, and the Pacific Northwest. In terms of total square footage, the vast majority of Hudson Pacific's real estate portfolio is composed of office properties located in the Greater Seattle, San Francisco, and Los Angeles areas. The company operates in two reportable segments; office properties & related operations; and studio properties & related operations. The majority of revenue is derived from the office properties & related operations segment.
About ESPR Esperion Therapeutics Inc.
Esperion Therapeutics Inc is a pharmaceutical company. It specializes in developing and commercializing accessible, oral, once-daily, non-statin medicines for patients struggling with elevated low-density lipoprotein cholesterol. The firm has the business of researching, developing and commercializing therapies for the treatment of patients with the elevated low-density lipoprotein cholesterol operating segment. Its products include NEXLETOL, NEXLIZET, NILEMDO and NUSTENDI. The Company manages its business in one operating segment, which is the business of researching, developing and commercializing therapies for the treatment of patients with elevated LDL-C.